Is ANAPTYSBIO, INC (ANAB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 24.9% / 30% | 2.6% / 30% | 21.68% / 5% | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 24.9% / 33% | 2.6% / 33% | 21.68% / 5% | ✗ NOT HALAL |
| MSCI | 3.3% / 33% | 79.6% / 33% | 8.4% / 33% | 21.68% / 5% | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 24.9% / 33% | 2.6% / 33% | 21.68% / 5% | ✗ NOT HALAL |
| FTSE | 3.3% / 33% | 79.6% / 33% | 8.4% / 50% | 21.68% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 42.0% | |
| Operating Margin | 61.8% | |
| Net Margin | -5.6% | |
| Return on Equity (ROE) | -24.5% | |
| Return on Assets (ROA) | 7.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $20M |
| Free Cash Flow | $20M |
| Total Debt | $14M |
| Debt-to-Equity | 781.1 |
| Current Ratio | 9.1 |
| Total Assets | $364M |
Price & Trading
| Last Close | $64.99 |
| 50-Day MA | $55.16 |
| 200-Day MA | $37.18 |
| Avg Volume | 520K |
| Beta | 0.4 |
|
52-Week Range
$15.40
| |
About ANAPTYSBIO, INC (ANAB)
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ANAPTYSBIO, INC (ANAB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ANAPTYSBIO, INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ANAPTYSBIO, INC's debt ratio?
ANAPTYSBIO, INC's debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.3%.
What are ANAPTYSBIO, INC's key financial metrics?
ANAPTYSBIO, INC has a market capitalization of $1.7B, and revenue of $235M. The company maintains a gross margin of 42.0% and a net margin of -5.6%. Return on equity stands at -24.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.